CREATE Medicines
CREATE, formerly Myeloid Therapeutics, disclosed preclinical in vivo CAR-T/CAR-NK and all-RNA RetroT work at AACR 2026. Clinical MT-302 is a myeloid-cell program, not evidence that its CAR-T programs have reached the same stage. The former name is retained as an alias.
Corporate information
- Company entity
- CREATE Medicines
- Headquarters / principal office
- Cambridge, Massachusetts, United States ↗
- Founded
- Not verified
- Ownership / capital status
- PrivateSeries B (announced May 2026) ↗
- Official corporate reference
- https://createmedicines.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2026-05-14 · Series B · US$122 million ↗
Closed financing announced by company; not a cumulative funding total.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
CREATE, formerly Myeloid Therapeutics, disclosed preclinical in vivo CAR-T/CAR-NK and all-RNA RetroT work at AACR 2026. Clinical MT-302 is a myeloid-cell program, not evidence that its CAR-T programs have reached the same stage. The former name is retained as an alias.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- CREATE Medicines — primary program / ownership disclosure
- CREATE Medicines | In Vivo Immune Programming with RNA-CAR Therapies
- CREATE Series B financing, 14 May 2026